Kornimate/medical-research-clean huggingface dataset:
assessment of the efficacy of ocular dipyridamole in the treatment of dry eye symptomology in subjects with pterygium

Conditions: Dry Eye Syndromes; Pterygium

Summary: subjects with pterygium and associated dry eye symptoms (des) are randomized into an active cohort (receiving ocular administration of dipyridamole) or placebo cohort (ocular administration of vehicle). monthly follow up is conducted for 12 months. testing conducted at follow up will assess dry eye / pterygium symptoms and endpoints and review the efficacy of the intervention.


Eligibility criteria:
inclusion criteria: * able to provide informed consent. * ineligible or refused surgical excision, or had recurrence of pterygium following surgical excision * able to follow the study instructions, including application of the study product * agreement not to change the type of lubricating eye drops used (if any) during their participation in the study. * assessed as having at least pterygium stage 0-1 (pinguecula) based on johnston, williams \& sheppard's classification for pterygium * concomitant dry eye symptoms, as determined by one or more of the following subject interview (modified ocular surface disease index test), tearing, itch / foreign body sensation, positive fluorescein test, positive tbut test, positive tear meniscus test exclusion criteria: * inability to provide informed consent * dry eye due to other factors * known lacrimal obstruction * contact lens wearers * non-corrected refraction * allergy or sensitivity to dipyridamole or excipients * use of dipyridamole in the last 6 months * other eye conditions (i.e. active ocular infection, herpes keratitis in last 6 months, corneal disorder abnormality excluding pterygium, history of ocular acne rosacea, blepharitis) which would impact results * diagnosis of als (amyotrophic lateral sclerosis) * existing conditions which are contraindicated or precaution in use of dipyridamole or excipients * use of eye drops (other than ocular lubricants) * pregnant or breastfeeding * inability to apply the medical product or follow the study procedures * anything that the pi thinks would impact the trial
effects of three different methods applied to patients after spine surgery on nausea, thirst and comfort

Conditions: Spinal Surgery

Summary: the aim of this study was to determine the effects of postoperative methods on nausea, thirst and comfort levels of patients undergoing spinal surgery.

within the scope of this randomized controlled study, it is aimed to evaluate the effectiveness of ice, mouthwash and menthol lozenge interventions to provide effects on postoperative nausea, thirst and comfort in patients undergoing spinal surgery

Eligibility criteria:
inclusion criteria: * adult patients who underwent lumbar disc herniation (ldh) surgery * ldh surgery patients who recieve general anesthesia * the patients who were conscious * the duration of surgery is between 0-3 hours exclusion criteria: * patients who cannot understand and speak turkish * allergic patients to menthol * patients who received spinal anesthesia * patients with lesions on the oral mucosa and lips * patients requiring intensive care after surgical intervention

Keywords: nausea, thirst, comfort
clinical evaluation of two daily disposable silicone hydrogel contact lenses

Conditions: Myopia

Summary: the purpose of this crossover study was to evaluate the end-of-day comfort of two commercially available, daily disposable, silicone hydrogel contact lenses.


Eligibility criteria:
inclusion criteria: * sign written informed consent document. * currently wearing soft contact lenses in both eyes and identified as symptomatic based on questionnaire responses. * currently wearing either daily disposable contact lenses or weekly/monthly replacement contact lenses. * able to achieve visual acuity of at least 6/7.5 in each eye with study lenses in the available parameters. * willing to wear study lenses for at least eight hours per day and at least five days per week. * other protocol-defined inclusion criteria may apply. exclusion criteria: * has not worn contact lenses before. * currently wearing dailies total1 or 1-day acuvue trueye contact lenses. * any systemic or ocular disease or disorder that would negatively affect the conduct or outcome of the study. * ocular surgery/trauma within the last six months. * topical ocular or systemic use of antibiotics within seven days of enrollment. * pregnant or nursing women. * other protocol-defined exclusion criteria may apply.

Keywords: dailies total1 contact lenses myopia
oral azithromycin versus doxycycline in posterior blepharitis

Conditions: Posterior Blepharitis

Summary: one hundred patients with the diagnosis of posterior blepharitis based on history taking and proper physical examinations by two experienced ophthalmologists will include in the study. patients will diagnose with posterior blepharitis if they score at least one in two symptoms (based on a subjective grading scale) and two signs (based on an objective grading scale) of posterior blepharitis according to study criteria. patients will exclude if they have the following criteria: age\< 12 years old,history of previous ocular or lacrimal surgery,previous usage of contact lenses,any history of ocular allergy,history of systemic diseases with ocular involvement (except rosacea), history of usage of topical or systemic antibiotic in the last month, pregnancy or lactating mothers, liver failure and any history of sensitivity to cyclines. qualified patients then randomly receive oral azithromycin (2 of 250 mg capsules for the first day and 250mg for the next 4 days) or oral doxycycline (100mg capsule every 12 hours for one month) in a double-blinded fashion. each patients in both treatment groups will accurately instruct to apply warm compress and eyelid scrubbing 2 times a day for 5 minutes each in the treatment period. symptoms and signs were recorded for each patient in two treatment groups at baseline visit (before treatment) and then in the days 7, 31, 37 and 61 after treatment.


Eligibility criteria:
inclusion criteria: patients were diagnosed with posterior blepharitis if they scored at least one in two symptoms (based on a subjective grading scale) and two signs (based on an objective grading scale) of posterior blepharitis according to study criteria exclusion criteria: patients were excluded if they had the following criteria: age\< 12 years old,history of previous ocular or lacrimal surgery,previous usage of contact lenses,any history of ocular allergy,history of systemic diseases with ocular involvement (except rosacea), history of usage of topical or systemic antibiotic in the last month, pregnancy or lactating mothers, liver failure and any history of sensitivity to cyclines

Keywords: azithromycin doxycycline posterior blepharitis
study of low molecular weight heparins

Conditions: Anticoagulant; Venous Thromboembolism; Prophylaxis; Treatment

Summary: danhep is a cluster randomized study of two different low molecular weight heparins. parenteral anticoagulants are used in a variety of settings, including treatment and prevention of venous thromboembolism in cancer patients, medical patients, and surgical patients, along with the use as adjuvant therapy for coronary syndromes. the most frequently used parenteral anticoagulants in denmark, include the two different low molecular weight heparins; dalteparin and tinzaparin. the two drugs are considered equally efficient and safe regarding treatment and prevention of thrombosis and risk of bleeding. importantly, there is a lack of evidence regarding whether these drugs are in fact comparable. the aim of this study is therefore to investigate the comparative safety and efficacy of the two different low molecular weight heparins (dalteparin and tinzaparin using cluster randomization in patients with an indication for low molecular weight heparins.


Eligibility criteria:
inclusion criteria: * all patients with indication for low molecular weight heparin exclusion criteria: * patients under the age of 18 * patients who are incapable of understanding the written material received * patients who after being informed in writing chooses not to participate * patients with contraindications for low molecular weight heparins as described in the smpc
wheezing diagnosis using a smartphone

Conditions: Bronchiolitis

Summary: abnormal respiratory sounds (wheezing and/or crackles) are diagnosis criteria of acute bronchiolitis. one third of these infants will develop recurrent episodes, leading to the diagnosis of infant asthma. nowadays, no available treatment shortens the course of bronchiolitis or hastens the resolution of symptoms, thus, therapy is supportive. our hypothesis is that the diagnosis of wheezing during bronchiolitis (\~60% of infants) will help to select infants who will benefit from anti-asthma therapy. in this setting the diagnosis of wheezing is crucial, and an objective tool for recognition of wheezing is of clinical value. the investigators developed a wheezing recognition algorithm from recorded respiratory sounds with a smartphone placed near the mouth (bokov p, comput biol med, 2016). the objectives of the present cross sectional, observational study are 1/ to further validate our approach in a larger sample of infants (1 to 24 months) admitted to hospital for a respiratory complaint during the period of viral bronchiolitis, and 2/ to use gold standard diagnosis of wheezing by respiratory sound recording (littmann) and subsequent analysis by two experienced pediatricians.

infants (1 to 24 months old) are recruited in two emergency departments (robert debré; antoine béclère hospitals of assistance publique - hôpitaux de paris) based on a respiratory complaint. six characteristics are recorded (age, sex, spo2, presence or absence of wheezing, other respiratory sound, initial diagnosis). two recordings of respiratory sounds are obtained almost simultaneously: one with a smartphone at the mouth (5 cm) and one with an electronic stetoscope (littmann). two expert pediatricians listen the recordings giving thee groups: with wheezing (agreement), without wheezing (agreement) and non agreement diagnosis. the recordings made with the smartphone are subjected to the wheezing recognition algorithm as previously described. the sensitivity, specificity, ppv, npp are then evaluated. the algorithm will further be improved if necessary using the true negative and true positive recordings (those with expert agreement).

Eligibility criteria:
inclusion criteria: * infant 1 to 24 months old * respiratory complaint in the emergency room exclusion criteria:

Keywords: wheezing bronchiolitis respiratory sound algorithm
prevalence of abuse among patients with rheumatic diseases

Conditions: Rheumatic Diseases; Abuse Neglect; Abuse

Summary: patients with rheumatic diseases (rd) have a relevant representation in the adult population in mexico. rd are characterized by their chronic and progressive nature, which can impact functionality during the disease and can present various factors that can be associated with the presence of abuse, among others, economic dependence, decreased physical capacity, and need for care and support in different health processes. regarding abuse in patients with rd, there is little information in the literature; however, it is possible that the prevalence could be similar to that of the occurrence in older adults since both populations share important states of vulnerability. the study aimed to identify the prevalence of abuse in patients with rd. the study will be conducted in two phases: the first one in which the gas will be adapted for patients with rd, and this version will be validated in a population of our institute, and the second one in which, applying the validated instrument, the magnitude of abuse is evaluated, and the factors associated with this phenomenon among patients with rd are explored.

patients with rheumatic diseases (rd) have a relevant representation in the adult population in mexico. rd are characterized by their chronic and progressive nature, which can impact functionality during the disease and can present various factors that can be associated with the presence of abuse, among others, economic dependence, decreased physical capacity, and need for care and support in different health processes. in 1970, the phenomenon of abuse in geriatric patients was described for the first time as a phenomenon identified as a public health problem and an issue of human rights violation. in 2012 giraldo-rodríguez developed and validated the geriatric abuse scale (gas), an instrument that, with adequate psychometric properties, reported a prevalence of abuse of 10.28% in mexico. regarding abuse in patients with rd, there is little information in the literature; however, it is possible that the prevalence could be similar to that of the occurrence in older adults since both populations share important states of vulnerability. the study aimed to identify the prevalence of abuse in patients with rd. the study will be conducted in two phases: the first one in which the gas will be adapted for patients with rd, and this version will be validated in a population of our institute, and the second one in which, applying the validated instrument, the magnitude of abuse is evaluated, and the factors associated with this phenomenon among patients with rd are explored.

Eligibility criteria:
inclusion criteria: * patients with a rheumatic disease diagnosis according to their primary rheumatologist who agree to participate exclusion criteria: * patients with a not confirmed rheumatic disease

Keywords: rheumatic diseases abuse
evaluation of levator injuries using transvaginal endosonography

Conditions: Childbirth Related Levator Injuries

Summary: prospective studies to date have identified that the levator ani muscle injuries occur in 14-19% of women after vaginal delivery. in none of studies a vaginal examination was performed at the time of delivery. it has previously been shown that sonographic injuries of the anal sphincter that were believed to be occult were in fact clinically apparent but not recognised at the time of delivery. it is therefore important to correlate clinical findings to ultrasound images. 3d endovaginal endosonography has not previously been used to identify levator injuries. this should potentially provide a better view of the pelvic floor muscles. the relationship between levator injury and symptoms of pelvic floor dysfunction has not been previously established using validated questionnaires. in this study, we include validated questionnaires to evaluate urinary incontinence, faecal incontinence and vaginal symptoms. as symptoms may become apparent only in the long term it is prudent that the women are followed up in the long term. the principle objective is to establish the incidence of levator muscle defects during pregnancy and after childbirth. the levator muscle forms a major part of the pelvic floor and damage to this muscle can potentially cause urinary, bowel and sexual problems and pelvic organ prolapse.


Eligibility criteria:
inclusion criteria: 1. pregnant women who have not delivered previously 2. singleton pregnancy 3. maternal age \> 18 years and 4. no previous pregnancies \>20 weeks of gestation 5. ability to read and understand english. exclusion criteria: 1. pregnant women who have delivered previously 2. multiple pregnancies
comparison of two dosing regimens of temozolomide in patients with progressive or recurrent glioblastoma

Conditions: Glioblastoma

Summary: for patients with progressive or recurrent glioblastoma there is no standard therapy. one strategy is re-exposure to temozolomide in a higher dose. this increase in dosing can be done by 2 regimens. aim of this study is to compare these 2 dosing regimens concerning toxicity. in study arm a patients receive temozolomide for one week, followed by a week without temozolomide. in study arm b patients receive temozolomide for three weeks, followed by a week without temozolomide. the regimen that is less toxic will be selected for further evaluations.


Eligibility criteria:
inclusion criteria: * progressive or recurrent glioblastoma documented by mri no earlier than 180 days after first surgery for glioblastoma and no earlier than 90 days after completion of radiotherapy. * histological diagnosis of glioblastoma * tissue available for the determination of mgmt promoter methylation in the primary tumor or from the recurrent tumor if a patient undergoes a surgical procedure at recurrence prior to study entry. * prior treatment with temozolomide administered concomitantly with radiotherapy and at least for two cycles (5/28) as an adjuvant treatment * informed consent * age 18-80 years * karnofsky performance score \> 50% * neutrophil counts \> 1 500/µl * platelet counts \> 100 000/µl * hemoglobin \> 10 g/dl * serum creatinin \< 1.5-fold upper normal range * asat or alat \< 3-fold upper normal range unless attributed to anticonvulsants * alkaline phosphatase \< 3-fold upper normal range * women with childbearing potential must have a negative serum pregnancy test ≤14 days prior to study enrollment * willingness to apply contraception according to local requirements (as stated in patient information) exclusion criteria: * progressive or recurrent glioblastoma documented by mri earlier than 180 days after first surgery for glioblastoma and earlier than 90 days after completion of radiotherapy. * treatment with any chemotherapy other than temozolomide according to the schedule of the eortc ncic trial (stupp et al. n engl j med 2005;352:987-996) except that an adjuvant starting dose of 200 mg/m2 and more than 6 cycles of adjuvant temozolomide are allowed * prior systemic or local treatment with dna-damaging agents, tyrosine kinase inhibitors or anti-angiogenic agents for any cancer * allergy to or other intolerability of temozolomide * unable to undergo mri * past medical history of diseases with poor prognosis, e.g. severe coronary heart disease, severe diabetes, immune deficiency, residual deficits after stroke, severe mental retardation * hiv infection * pregnancy * breast feeding * treatment within in any other clinical trial parallel to the treatment phase of the current study

Keywords: progressive or recurrent glioblastoma temozolomide dose intensification comparison of two dosing regimens
biodegradable stenting anastomoses versus double-layer hand sutures for reconstruction in intestinal anastomosis

Conditions: Colonic Neoplasms; Diverticulosis, Colonic; Crohn Disease

Summary: intestinal anastomosis plays an important role in various general surgeries, but the complications such as anastomotic leakage,stenosis and hemorrhage cannot been avoided. although many ways are put up to solve this problem, there are still many imports need to improve. therefore, the biodegradable stenting anastomoses(bsa), which make intestinal anastomosis easily and less complications, have been produced.the major goal of this study is to evaluate the efficacy of biodegradable stenting anastomoses(bsa) for reconstruction in surgery of intestinal anastomosis.


Eligibility criteria:
inclusion criteria: * patients with age between 18 - 80 years. * patients with operation of end to end anastomosis of colon or small intestine. * patients without previous surgery during 3 months. * patients who understand the nature of this trial and provide informed consent. exclusion criteria: * patients with severe cardiopulmonary disease or other severe disease. * patients who are psychopath, pregnant, and child without capacity for civil conduct. * patients with complete intestinal obstruction. * patients with abdominal cavity infection. * patients who are treating by drug such as adrenal cortical hormone and immune inhibitors, chemotherapy drugs, radiation and so on. * patients who need to accept the anastomosis between rectum and colon. * patients who are required to accept intestinal anastomosis twice or more. * patients who are required to accept the treatment of colostomy. * other conditions that render a patient unsuitable for the trial as determined by the study investigators.

Keywords: intestinal reconstruction end to end anastomosis
a multiple dose comparison of tiotropium inhalation capsules and salmeterol inhalation aerosol.

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the objective of the study was to evaluate the degree of improvement in lung function in patients with chronic obstructive pulmonary disease (copd) after treatment with tiotropium inhalation capsules compared to salmeterol inhalation aerosol .


Eligibility criteria:
inclusion criteria: * ability to sign a written informed consent form consistent with international conference of harmonization-good clinical practice (ich-gcp) guidelines prior to participation in the trial (i.e., prior to any study procedures, including any pre-study washout of medications). * age of 40 years or older. * smoking history of ≥10 pack-years. * a diagnosis of relatively stable chronic obstructive pulmonary disease with an forced expiratory volume in one second (fev1) ≤60% of predicted normal and fev1 ≤70% of forced vital capacity (fvc). * ability to perform technically acceptable pulmonary function tests, and ability to maintain records during the study period as required in the protocol. * ability to inhale medication from the handihaler® and from a metered dose inhaler. exclusion criteria: * clinically significant diseases other than chronic obstructive pulmonary disease (copd). a clinically significant disease was defined as a disease or condition which, in the opinion of the investigator, could have put the patient at risk because of participation in the study or may have influenced either the results of the study or the patient's ability to participate in the study. * known moderate or severe renal insufficiency. * a recent history (i.e., six months or less) of myocardial infarction. * unstable or life-threatening cardiac arrhythmias, including newly diagnosed, clinically relevant arrhythmia on the electrocardiogram (ecg) performed on visit 1. unstable arrhythmias included arrhythmias that required an intervention (i.e., hospitalization, cardioversion, pacemaker placement, and automatic implantable cardiac defibrillator (aicd) placement) or a change in drug therapy during the year preceding study enrollment. * hospitalization for heart failure during the past three years. * history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis. * other exclusion criteria apply.
technique for localization of pulmonary nodules using spy thoracoscope system

Conditions: Lung Cancer

Summary: this study will determine the feasibility of the novel indocyanine green (icg) fluorescence localization technique with a laser fluorescence thoracoscope system. the primary objective of this study is to prove the validity and safety of our novel fluorescent localization method with utilized icg and novel near infra-red fluorescence videoscope system.


Eligibility criteria:
inclusion criteria: * any patient scheduled for a vats wedge lung resection using ct guided micro-coil lung implantation for the localization of the lung lesion. exclusion criteria: * any patients with an allergy to iodine, shellfish, or cough mixture, betadine or other iodine contrast agents. * pregnant or potentially pregnant women.